---
title: "Ayala Pharmaceuticals (ADXS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ADXS.US.md"
symbol: "ADXS.US"
name: "Ayala Pharmaceuticals"
industry: "Biotechnology"
---

# Ayala Pharmaceuticals (ADXS.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States. The company is developing AL102, an oral gamma secretase inhibitor ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:15.000Z

**Overall: D (0.79)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -98.12% |  |
| Net Profit YoY | -26.46% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 13000.00 |  |


**Multi Score**: D

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 376.80% | A |
| Profit Margin | -369784.62% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -98.12% | E |
| Net Profit YoY | -26.46% | D |
| Total Assets YoY | 113.40% | A |
| Net Assets YoY | -2121.75% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.03% | D |
| OCF YoY | -98.12% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 247.28% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Ayala Pharmaceuticals",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "376.80%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-369784.62%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-98.12%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-26.46%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "113.40%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-2121.75%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.03%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-98.12%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "247.28%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | Abbvie (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.03 | 78/605 | - | - | - |
| PB | -0.07 | 504/605 | - | - | - |
| PS (TTM) | 126.28 | 306/605 | 126.28 | 126.28 | 126.28 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/ADXS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ADXS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ADXS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.